Related Experiment Video
Updated: Jan 5, 2026
Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis
Published on: July 18, 2017
Eravacycline for the treatment of complicated intra-abdominal infections
Philippe Montravers1,2, Nathalie Zappella2, Alexy Tran-Dinh2,3
1INSERM UMR 1152, Université de Paris, Paris, France.
Insights
Eravacycline, a novel fluorocycline antibiotic, shows strong antimicrobial activity against common pathogens in complicated intra-abdominal infections (cIAIs). Clinical trials confirm its non-inferiority to carbapenems with a favorable safety profile.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Complicated intra-abdominal infections (cIAIs) present significant morbidity and healthcare burdens.
- Existing treatments face challenges due to limited spectrum and resistance, particularly against multidrug-resistant bacteria.
- Eravacycline, a synthetic fluorocycline, offers potential for improved cIAI management.
Purpose of the Study:
- To evaluate the antimicrobial activity, pharmacokinetic properties, and clinical efficacy of eravacycline for treating cIAIs.
- To assess eravacycline's safety profile in comparison to established treatments.
- To explore eravacycline's suitability for diverse patient populations, including those with renal impairment or elderly individuals.
Main Methods:
- Worldwide clinical isolates were tested for antimicrobial susceptibility to eravacycline.
- Pharmacokinetic studies assessed tissue distribution, particularly in biliary and digestive tracts.
- Phase 2 and 3 clinical trials compared eravacycline's efficacy and safety against carbapenems.
Main Results:
- Eravacycline demonstrated broad-spectrum activity against key cIAI pathogens, including resistant strains.
- Favorable pharmacokinetic properties were observed, with good tissue penetration.
- Clinical trials showed eravacycline to be non-inferior to carbapenems with an acceptable safety profile.
- No dosage adjustments were needed for elderly patients, those with renal impairment, or on hemodialysis.
Conclusions:
- Eravacycline exhibits promising antimicrobial and pharmacokinetic characteristics for cIAI treatment.
- Clinical trial data support its efficacy and safety, comparable to carbapenems.
- Further real-world data in specific patient subgroups will confirm its therapeutic role.
Abstract:
Introduction: Complicated intra-abdominal infections (cIAIs) are among the most frequent infections, contributing to significant morbidity and healthcare costs. Several medical needs remain unmet, related to the pharmacokinetic capacities of the available drugs and their limited spectrum of activity for targeting multidrug-resistant Gram-negative and Gram-positive bacteria. Eravacycline, a new synthetic fluorocycline, could have useful properties in cIAIs.Areas covered: The antimicrobial activity of eravacycline against the microorganisms most frequently cultured in cIAIs has been confirmed in worldwide panels of clinical isolates, including enterococci, ESBL-producing Enterobacteriaceae, Acinetobacter baumannii and anaerobes. Pharmacokinetic data demonstrate interesting characteristics with good tissue concentrations including biliary tract and digestive tissues. At a conventional dosage of 1 mg/kg q12h, no adjustment is required on the basis of race or gender, or in elderly (≥ 65 years old) patients, patients with renal impairment or patients undergoing hemodialysis. Phase 2 and 3 trials assessing the clinical efficacy and safety of eravacycline demonstrated non-inferiority versus carbapenems and a good safety profile.Expert opinion: Eravacycline may be particularly suitable for the treatment of cIAIs. Results from clinical trials and real-world data are now expected in specific subgroups of patients to confirm the safety profile and efficacy observed in registration trials.
More Related Videos
04:01Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis
Published on: September 8, 2022
03:25Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy
Published on: June 16, 2022
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:17Urinary Tract Infection IV: Nursing Management
01:27Acute Pyelonephritis I: Introduction
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy